An experimental and theoretical approach for an estimation of DKth

The existence of a fatigue threshold value may affect the design process when a damage-tolerant design is considered that uses non-destructive techniques for evaluating the shape and dimensions of the defects inside materials. Obviously it should be possible to estimate the stress field surrounding these defects and this is not generally a problem with modern numerical methods.Many factors are involved in determining the growth rate of a fatigue crack. Some of these are highly significant and it is possible to obtain the coefficients of a correlation function. Some others are not well defined and the only effect is to expand the scatter of experimental data.Consider the sigmoidal curve we obtain when plotting the crack growth rate versus the applied DK_I . A very difficult parameter to measure but very useful for fatigue design is the DK_Ith value, because below this value a crack may be forming, hence, here DK_Ith is defined by the transition between a normal (e.g. 10-10 m/cycle) and a very low range of crack growth rate (<10-10 m/cycle).The DgrKIth value is very difficult to obtain by experimental methods because the growth rate is of the order or less than the atomic lattice span (3 × 10-10 m/cycle), but we can correlate the transition value with the cyclic crack tip plastic zone size and other structural parameters of metallic materials.The aim of this work is to offer a contribution about the parameters which influence DK_Ith in stainless steels and welded joints based on the crack tip plastic zone radius

Modello di calcolo del limite di fatica di materiali metallici contenenti difetti di solidificazione e di lavorazione

Il calcolo della resistenza a fatica di componenti ed elementi strutturali contenenti difetti e disomogeneità ha trovato negli ultimi anni uno sviluppo nell’ambito della teoria degli small-and short cracks. Il principio è quello di considerare i difetti con lo stesso formalismo della meccanica della frattura, tenendo presente che il fattore di intensificazione degli sforzi è diverso a seconda della geometria del difetto ed introducendo quindi un indice di sensibilità all’intaglio per ogni tipo di difetto. In questo studio viene effettuata un’analisi dell’ equazione di Murakami-Endo per predire la resistenza a fatica in funzione della difettologia del materiale e viene formulata una equazione alternativa che considera sia il valore del KIc del materiale metallico che quello del Kt all’apice del difetto. I valori del limite di fatica calcolati con il metodo di Murakami-Endo e con quello degli autori sono confrontati con quelli ottenuti in via sperimentale su alcune leghe di alluminio e su un acciaio da costruzione

Normal scaling in globally conserved interface-controlled coarsening of fractal clusters

Globally conserved interface-controlled coarsening of fractal clusters exhibits dynamic scale invariance and normal scaling. This is demonstrated by a numerical solution of the Ginzburg-Landau equation with a global conservation law. The sharp-interface limit of this equation is volume preserving motion by mean curvature. The scaled form of the correlation function has a power-law tail accommodating the fractal initial condition. The coarsening length exhibits normal scaling with time. Finally, shrinking of the fractal clusters with time is observed. The difference between global and local conservation is discussed.Comment: 4 pages, 3 eps figure

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

Background: The EMPA KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. Methods: EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110. Findings: Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5–2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62–0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16–1·59), representing a 50% (42–58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all >0·1). Interpretation: In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease. Funding: Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council

Use of Instrumented Charpy Impact Tests for the Determination of Fracture Toughness Values

There were many attempts to correlate Charpy absorbed energy with fracture parameters. Most of these gave empirical or semi-theoretical equations showing this correlation. In the present paper the dynamic yield strength is used to obtain the relation between Charpy V and KIC. Comparison is made between three structural steels (1.0570 – 1.0511 – 1.8900) and the alloy Ti-Al6-V4. For the steels, fracture toughness experimental values are coherent with those based on data determined with the derived relation. For Ti-Al6-V4 the values deviate from each other, particularly at room temperature, when the contribution of α-phase is more important

Modello di calcolo del limite di fatica di materiali metallici contenenti difetti di solidificazione e di lavorazione

Viene effettuata un'analisi dell'equazione di Murakami-Endo per predire la resistenza a fatica in funzione della difettologia del materiale e viene formulata una equazione alternativa che considera sia il valore del KIc del materiale metallico che quello del Kt all'apice del difetto. I valori del limite di fatica calcolati con il metodo di Murakami-Endo e con quello degli autori sono confrontati con quelli ottenuti in via sperimentale su alcune leghe di alluminio e su un acciaio da costruzione

Fatigue threshold in aluminium alloys

The fatigue threshold of aluminum alloys has not been studied in detail in the near threshold region and the objective of the work reported here was to compare the behaviour of two traditional alloys (5754 and 6082) with two aluminium -lithium alloys (2091 and 8090) in the threshold stress intensity range

Assessment of Plasma Zinc and Total Leukocyte Count in Calves Experimentally Infected with Mannheimia haemolytica

Mannheimia haemolytica is the main bacterial pathogen isolated in bovine respiratory disease (BRD), a common disease affecting calves before weaning. Previous research has shown that experimental infection with bovine herpesvirus 1, a respiratory virus, decreases plasma zinc (Zn) levels. However, changes in plasma Zn concentrations in calves experimentally infected with M. haemolytica have not been studied thus far. The objective of this study was to evaluate the effect of experimental infection with M. haemolytica on plasma Zn concentration in calves. Total leukocyte count and bovine respiratory disease (BRD) clinical score were also evaluated. We conducted a 6-day trial in 14 male Holstein calves randomly assigned to one of two groups, experimental (EG, n = 8) and control (CG, n = 6). Animals in EG were intrabronchially inoculated with M. haemolytica (6.5 × 106 CFU/mL) on day 0 of the trial. Plasma Zn levels were affected by time, treatment, and time by treatment interaction, being lower in EG compared with CG on days 1, 2, and 3. Differences in total leukocyte count were significant on day 1, observing a tendency on day 3. BRD clinical score differed between groups, being higher in EG throughout the trial. We conclude that experimental M. haemolytica infection reduced plasma Zn concentration in clinically ill calves, suggesting that the clinical condition of animals (healthy/ill) should be considered to better interpret plasma Zn values.Fil: Galarza, Esteban Martín. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico CONICET- La Plata. Instituto de Genética Veterinaria "Ing. Fernando Noel Dulout". Universidad Nacional de La Plata. Facultad de Ciencias Veterinarias. Instituto de Genética Veterinaria; Argentina. Universidad Nacional de La Plata; ArgentinaFil: Lizarraga, Raúl Martín. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico CONICET- La Plata. Instituto de Genética Veterinaria "Ing. Fernando Noel Dulout". Universidad Nacional de La Plata. Facultad de Ciencias Veterinarias. Instituto de Genética Veterinaria; ArgentinaFil: Streitenberger, N.. Universidad Nacional de La Plata; ArgentinaFil: Arriaga, G.. Universidad Nacional de La Plata; ArgentinaFil: Abraham, G.. Universidad Nacional de La Plata; ArgentinaFil: Mattioli, Guillermo Alberto. Universidad Nacional de La Plata; ArgentinaFil: Anchordoquy, Juan Mateo. Universidad Nacional de La Plata; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico CONICET- La Plata. Instituto de Genética Veterinaria "Ing. Fernando Noel Dulout". Universidad Nacional de La Plata. Facultad de Ciencias Veterinarias. Instituto de Genética Veterinaria; ArgentinaFil: Fazzio, Luis Emilio. Universidad Nacional de La Plata; Argentin